Pfizer (NYSE: PFE) has been an underwhelming stock to own in recent years. Question marks about its growth and how it will do in the future, as it faces multiple patent cliffs, have resulted in investors steering away from the stock entirely. Despite persistently trading at a low valuation, there hasn't been a compelling reason for investors to load up on the stock -- it's down 38% over the past three years. There could, however, be one enticing reason to buy the stock, and that's for its dividend. At 6.3 ...